MVI’S Selection by RESI Conference Creates Opportunity to Showcase Its Cutting-Edge Life Science Technologies in a Poster Display and Competition


Opportunity to Connect, Dialogue, and Build Relationships with Investors


San Francisco, January 12, 2016 – Madison Wisconsin and San Francisco, CA - January 12, 2016 - Madison Vaccines Incorporated (MVI), is pleased to announce that it is one of a select group of innovative companies tapped to provide a poster exhibit at the Redefining Early Stage Investments (RESI) Conference’s RESI Innovation Challenge. The poster exhibit will take place January 12, 2016, 7 am to 8 pm at the Marine’s Memorial Club & Hotel, 609 Sutter St., San Francisco.


link to RESI Conference


RESI is an ongoing conference series with a goal of establishing a global circuit for early stage life science companies, active investors, and various service providers to meet, create dialogues and start relationships - ultimately moving science and technology forward. Conference attendees are tasked with voting on the Poster Exhibits and the top three receive cash awards and widespread exposure.


"This represents an important opportunity for MVI to convey its key messages to diverse investors that are a fit for our technology sector and stage of development,” said Richard R. Lesniewski, PhD, President and CEO, MVI. “Our objective is to deliver safe, effective and economical vaccine therapies for men at all stages of prostate cancer, however MVI is working uniquely on the unmet need to attack early prostate disease, while competitors are focusing only on terminal stages of the disease. This sets MVI apart and provides a unique opportunity for investors."


The RESI Conference, which has a strong track record of attracting global early stage investors, is held in conjunction with one of the largest, and globally well-known biopharmaceutical industry events, the 34th Annual JP Morgan Healthcare Conference, January 11-14, 2016, San Francisco.


More than 150 CEO’s and early stage investors will convene from around the globe for the RESI Conference, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.




About MVI


Wisconsin-based MVI is developing two plasmid DNA vaccines to treat men with prostate cancer. MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison.  More information is available at

Latest Articles:

Peer-Reviewed Paper Demonstrates How MVI-118 Works in Combination with Androgen Deprivation Therapy in advanced prostate cancer






Return to News